期刊文献+

第四批人凝血因子VIII国家标准品制备和标定 被引量:5

Preparation and Collaborative Calibration of 4th National Standard for Human Blood Coagulation Factor VIII Concentrate
下载PDF
导出
摘要 目的:建立经两步病毒灭活工艺制备的人凝血因子VIII国家标准品,以替代第三批人凝血因子VIII国家标准品。方法:按《中国药典》2010年版三部对人凝血因子VIII产品的生产工艺要求和质量标准,制备第四批人凝血因子VIII国家标准品(批号20100101),用WHO第七批人凝血因子VIII国际标准品(批号99/678),采用一期法进行协作标定,采用加速破坏试验进行稳定性考察。结果:批号20100101人凝血因子VIII国家标准品效价为12.1IU/支,稳定性好,其它项目指标均达到国家标准品的要求。结论:建立了符合国家标准品要求、并经病毒灭活的第四批人凝血因子VIII国家标准品。 Objective: Establishing 4th National Standard for Human Blood Coagulation Factor Ⅷ Concentrate which including two vi-ral inactivated steps in producing from fresh frozen human plasma. Methods:Using WHO 7th International Standard Human Blood Co-agulation Factor Ⅷ Concentrate and one-stage clotting method. Results: The potency of 4th National Standard Human Blood Coagula-tion Factor Ⅷ Concentrate( lot. 20100101 ) is 12. 1 IU/vial. Conclusion: Established 4th National Standard Human Blood Coagulation Factor Ⅷ Concentrate.
出处 《中国药品标准》 CAS 2013年第3期188-190,共3页 Drug Standards of China
关键词 人凝血因子Ⅷ国家标准品 制备 标定 national standard for human blood coagulation factor Ⅷ concentrate preparation calibration
  • 相关文献

参考文献1

共引文献1

同被引文献43

  • 1CNASGL03:2006能力验证样品均匀性和稳定性评价指南[S].
  • 2Fang H, Wang L, Wang H. The protein structure and effect of factor V: [J]. Thromb Res, 2007, 119(1): 1-13.
  • 3Baud'huin M, Duplomb L, T61etch:a S, et aL Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival [J]. J Biol Chem, 2009, 284(46): 31704- 31713.
  • 4Woodhams B, Girardot O, Blanco MJ, et ol. Stability of coagulation proteins in frozen plasma [J]. Blood Coagul Fibrinolysis, 2001, 12(4) : 229-236.
  • 5Yousef H, Neurath D, Freedman M, et al. Cryoprecipitate production: the use of additives to enhance the yield [J]. Clin Lab Haematol, 2006, 28(4): 237-240.
  • 6Lihme A, Hansen MB, Andersen IV, et 01. A novel core fractionation process of human plasma by expanded bed adsorption chromatography [J]. Anal Biochem, 2010, 399( l ) : 102-109.
  • 7Branovic K, Gebauer B, Trescec A, et ol. Characterization of FⅦ concentrates produced by two methods incorporating double virus inactivation[J]. Appl Biochem Biotechnol, 1998, 69(2): 99-111.
  • 8Cheng E, Jinzenji D, Lorthiois AP, et al. Purification of coagulation factor Ⅶ using chromatographic methods. Direct chromatography of plasma in anion exchange resins [J]. Biotechnol Lett, 2010, 32(9): 1207-1214.
  • 9国家药品监督管理局.血液制品去除/灭活病毒技术方法及验证指导原则[s].国药监注[2002]160号.2002.
  • 10Chtourou S, Porte P, Nogr6 M, eta/. A solvent/detergent- treated and 15-nm filtered factor V : a new safety standard for plasma-derived coagulation factor concentrates [J ]. Vox Sang, 2007, 92 (4): 327-337.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部